Biblio
“Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1237-47, 2016.
, “Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.”, J Alzheimers Dis, vol. 52, no. 1, pp. 345-57, 2016.
, “Comparing the Effects of Multisensory Stimulation and Individualized Music Sessions on Elderly People with Severe Dementia: A Randomized Controlled Trial.”, J Alzheimers Dis, vol. 52, no. 1, pp. 303-15, 2016.
, “Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin.”, J Alzheimers Dis, vol. 61, no. 1, pp. 321-332, 2018.
, “Biological Factors Contributing to the Response to Cognitive Training in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 1, pp. 333-345, 2018.
, “Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.”, J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
, “Simultaneous Aerobic Exercise and Memory Training Program in Older Adults with Subjective Memory Impairments.”, J Alzheimers Dis, vol. 62, no. 2, pp. 795-806, 2018.
, “New Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 82, no. s1, pp. S51-S63, 2021.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.”, J Alzheimers Dis, vol. 94, no. 3, pp. 993-1004, 2023.
, “Advanced Alzheimer's Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial.”, J Alzheimers Dis, vol. 96, no. 2, pp. 759-766, 2023.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “Dysregulation and Dislocation of SFPQ Disturbed DNA Organization in Alzheimer's Disease and Frontotemporal Dementia.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1311-1321, 2018.
, “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
, “Dogs with Cognitive Dysfunction as a Spontaneous Model for Early Alzheimer's Disease: A Translational Study of Neuropathological and Inflammatory Markers.”, J Alzheimers Dis, vol. 52, no. 2, pp. 433-49, 2016.
, “Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.”, J Alzheimers Dis, vol. 64, no. s1, pp. S47-S105, 2018.
, “Association Between Serum Ceruloplasmin Specific Activity and Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1181-9, 2016.
, “LRP/LR Antibody Mediated Rescuing of Amyloid-β-Induced Cytotoxicity is Dependent on PrPc in Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 645-57, 2016.
, “Aging as a Precipitating Factor in Chronic Restraint Stress-Induced Tau Aggregation Pathology, and the Protective Effects of Rosmarinic Acid.”, J Alzheimers Dis, vol. 49, no. 3, pp. 829-44, 2016.
, “Morroniside-Induced PP2A Activation Antagonizes Tau Hyperphosphorylation in a Cellular Model of Neurodegeneration.”, J Alzheimers Dis, vol. 51, no. 1, pp. 33-44, 2016.
, “Prion Protein-Hemin Interaction Upregulates Hemoglobin Synthesis: Implications for Cerebral Hemorrhage and Sporadic Creutzfeldt-Jakob Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 107-21, 2016.
, “A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Increases Dendritic Spine Density via RasGRF1/ERK Pathway.”, J Alzheimers Dis, vol. 51, no. 2, pp. 591-604, 2016.
, “Inhibition of Cholesterol Biosynthesis Reduces γ-Secretase Activity and Amyloid-β Generation.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1057-68, 2016.
, “PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway.”, J Alzheimers Dis, vol. 57, no. 3, pp. 723-734, 2017.
,